85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details

臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210

10 trials found

diseases per page:

Showing 1 to 10 of 10 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs051200109	18/01/2021	15/01/2021	DREAM study	A multicenter, open-label, prospective study of durvalumab, etoposide, and carboplatinfor unresectab ...	Small cell lung cancer	Patients will receive etoposide(<75 years old: 100mg/m2; >=75 years old: 80mg/m2; intravenously on d ...	Fujimoto Daichi	NULL	Recruiting	>= 20age old	Not applicable	Both	22	N/A	Japan
2	JPRN-jRCTs031190119	28/10/2019	18/10/2019	A phase II Study of CBDCA + ETP + Nintedanib for SCLC with IPF	A Phase II Study of Carboplatinand Etoposide Plus Nintedanib for Unresectable Limited/Extensive Dise ...	Unresectable limited or extensive disease small cell lung cancer with idiopathic pulmonary fibrosis	The patients receive carboplatin(area under the curve 5 mg/mL, intravenously, day 1), etoposide(<75 ...	IKEDA Satoshi	OGURA Takashi;Thoracic Oncology Research Group	Recruiting	>= 20age old	Not applicable	Both	33	Phase 2	Japan
3	JPRN-jRCTs071180049	23/05/2017	15/03/2019	Japanese Intergroup Study of Nintedanib for NSCLC with IPF	A randomized phase III study of carboplatinplus nab-paclitaxel with or without nintedanib for advanc ...	Advanced Non-small cell lung cancer with idiopathic pulmonary fibrosis	carboplatin + nab-paclitaxel carboplatin + nab-paclitaxel + nintedanib	Okamoto Isamu	Otsubo Kohei	Not Recruiting	>= 20age old	Not applicable	Both	240	Phase 3	Japan
4	JPRN-UMIN000026799	2017/05/12	01/04/2017	A randomized phse 3 study of carboplatinplus nab-paclitaxel with or without nintedanib for advanced ...	A randomized phse 3 study of carboplatinplus nab-paclitaxel with or without nintedanib for advanced ...	Non-small-cell lung cancer with idiopathic pulmonary fibrosis	A: 4 cycles of Carboplatin(AUC 6, day 1) plus nab-Paclitaxel(100 mg/m2, day 1, 8, 15) repeated every ...	Research Institute for Diseases of the Chest, Kyushu University	NULL	Complete: follow-up continuing	20years-old	Not applicable	Male and Female	240	Phase 3	Japan
5	JPRN-UMIN000021591	2016/04/04	01/04/2016	The pilot study of Nintedanib and Carboplatinplus Paclitaxel for advanced non-small cell lung cancer ...	The pilot study of Nintedanib and Carboplatinplus Paclitaxel for advanced non-small cell lung cancer ...	Advanced non-small cell lung cancer with idiopathic interstitial pneumonia	carboplatin AUC6 D1 paclitaxel 200mg/m D1 tryweekly 4cycle nintedanib 150mg twice daily	Hirosaki University Graduate School of Medicine	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	30	Not selected	Japan
6	JPRN-jRCTs051180149	24/01/2013	20/03/2019	CBDCA plus PTX for NSCLC (squamous) with IP	Phase II study of carboplatinplus weekly paclitaxel for advanced squamous cell lung cancer with idio ...	Squamous cell lung cancer Lung cancer	Carboplatin(AUC=5) given on day1 and paclitaxel(70mg/m2) given on days 1,8,15 every 4weeks until dis ...	Katakami Nobuyuki	NULL	Complete	>= 20age old	Not applicable	Both	40	Phase 2	Japan
7	JPRN-jRCTs061180046	17/01/2013	12/03/2019	CBDCA, PTX and BV for NSCLC (non-sq) with IP	Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non ...	Non-squamous, non-small cell lung cancer Lung cancer	Carboplatin(AUC=5) given on day1, paclitaxel(70mg/m2) given on days 1,8,15 and bevacizumab(15mg/m2) ...	Katakami Nobuyuki	NULL	Complete	>= 20age old	Not applicable	Both	35	Phase 2	Japan
8	JPRN-UMIN000018322	2012/12/01	15/07/2015	Phase II study of carboplatin, weekly paclitaxel and bevacizumab for advanced non-squamous cell, non ...		advanced non-squamous cell, non-small-cell lung cancer with idiopathic interstitial pneumonia	carboplatinAUC = 5, day1 paclitaxel70mg/m2, day1 ,8 ,15 bevacizumab15mg/kg, day1 every 4 weeks, 4-6 cyc ...	IP lung cancer study group	NULL	Recruiting	20years-old	Not applicable	Male and Female	35	Phase 2	Japan
9	JPRN-UMIN000018248	2012/12/01	09/07/2015	Phase II study of carboplatinplus weekly paclitaxel for advanced squamous cell lung cancer with idio ...		advanced squamous cell lung cancer with idiopathic interstitial pneumonia	Carboplatin AUC = 5 , day1 Paclitaxel 70mg/m2, day1,8,15 4-6 cycle	IP lung cancer study group	NULL	Recruiting	20years-old	Not applicable	Male and Female	40	Phase 2	Japan
10	JPRN-UMIN000015929	2007/05/10	12/12/2014	Prospective observational study of Idiopathic pulmonary fibrosis with Non-small-cell lung cancer(LOG ...		Idiopathic pulmonary fibrosis	Carboplatin/paclitaxelcombination therapy (dosage and administration) Paclitaxel(PAC):175-200mg/m2 at ...	Lung Oncology Group in Kyushu, Japan (LOGIK)	NULL	Complete: follow-up complete	20years-old	75years-old	Male and Female	60	Not selected	Japan

First Previous1Next Last